KMPH
(NASDAQ)
0.2204
-0.0118  (-5.37%)
Volume (24h): 974.97K Day Range: 0.2118 - 0.2377
Market Cap: 11.17M 52W Range: 0.1800 - 2.00
Mar-02-20 09:18PM KemPharm Submits KP415 NDA to the FDA for the Treatment of ADHDGlobeNewswire
Feb-28-20 12:30PM KemPharm Reports Fourth Quarter and Full-Year 2019 Financial ResultsGlobeNewswire
Jan-29-20 05:30PM 3 Healthcare Stocks That Can Double This YearTipRanks
Jan-15-20 01:30PM Nasdaq Grants KemPharm’s Request for Extension to Comply with the Market Value of Listed Securities Continued Listing RequirementGlobeNewswire
Dec-27-19 07:41PM Virgin Trains financing among biggest Orlando economic development deals of the yearAmerican City Business Journals
Dec-26-19 04:39PM UPDATED: C. Fla. pharmaceutical firm enters debt restructure agreementAmerican City Business Journals
Dec-24-19 08:39PM Central Florida pharmaceutical firm raises $71MAmerican City Business Journals
Dec-18-19 12:15PM KemPharm Announces Debt Restructuring with Deerfield and Delaware Street CapitalGlobeNewswire
Dec-04-19 08:42PM Edited Transcript of KMPH earnings conference call or presentation 14-Nov-19 10:30pm GMTThomson Reuters StreetEvents
04:12PM Edited Transcript of KMPH earnings conference call or presentation 14-Nov-19 10:30pm GMTThomson Reuters StreetEvents
Nov-14-19 09:55PM KemPharm Reports Third Quarter 2019 ResultsGlobeNewswire
Nov-12-19 01:30PM KemPharm to Report Third Quarter 2019 ResultsGlobeNewswire
Oct-31-19 12:30PM KemPharm Reports APADAZ® Will be Available Nationally Beginning in November 2019GlobeNewswire
Oct-22-19 08:15PM KemPharm Presents Study Highlighting Patient-Friendly Dosing Properties of KP415 at the 66th Annual American Academy of Child & Adolescent Psychiatry MeetingGlobeNewswire
Oct-03-19 02:56PM ArQule (ARQL) in Focus: Stock Moves 6.2% HigherZacks
01:21PM KemPharm, Inc. (NASDAQ:KMPH): What Does Its Beta Value Mean For Your Portfolio?Simply Wall St.
Sep-20-19 09:00PM KemPharm Provides Updates Regarding its Board of DirectorsGlobeNewswire
Sep-17-19 12:30PM KemPharm to Participate in the Oppenheimer Fall Summit Focused on Specialty Pharma & Rare DiseasesGlobeNewswire
Sep-04-19 12:00PM KemPharm Announces Entry into Definitive Collaboration and License Agreement for its ADHD Candidates, KP415 and KP484, with an Affiliate of Gurnet Point CapitalGlobeNewswire
Aug-13-19 09:00PM KemPharm Reports Second Quarter 2019 ResultsGlobeNewswire
Aug-07-19 02:59PM Implied Volatility Surging for KemPharm (KMPH) Stock OptionsZacks
Jul-05-19 02:13PM Could The KemPharm, Inc. (NASDAQ:KMPH) Ownership Structure Tell Us Something Useful?Simply Wall St.
May-14-19 08:05PM KemPharm Reports First Quarter 2019 ResultsGlobeNewswire
Apr-11-19 08:17PM KemPharm Completes KP415 Pre-NDA Meeting with FDAGlobeNewswire
Mar-15-19 09:41PM Edited Transcript of KMPH earnings conference call or presentation 28-Feb-19 9:30pm GMTThomson Reuters StreetEvents
Mar-13-19 11:30AM KemPharm Provides Update on APADAZ® Formulary AdoptionGlobeNewswire
Mar-07-19 03:58PM Loss-Making KemPharm, Inc. (NASDAQ:KMPH) Expected To BreakevenSimply Wall St.
KemPharm, Inc., a specialty pharmaceutical company, discovers and develops various proprietary prodrugs in the United States. The company's lead product candidates include KP415 and KP484, which are extended release prodrugs of methylphenidate for the treatment of attention deficit hyperactivity disorder. It also provides APADAZ, an immediate-release (IR) combination product candidate of benzhydrocodone and acetaminophen to treat the short-term management of acute pain. In addition, the company develops KP201/IR, an acetaminophen-free immediate-release formulation of APADAZ for treating short-term management of acute pain; and KP511/ER and KP511/IR hydromorphone product candidates for the treatment of pain. Further, it is developing KP606, a prodrug of oxycodone for the management of moderate to severe pain; KP746, a prodrug of oxymorphone for the management of moderate to severe pain; and KP303, a prodrug of quetiapine for the treatment of central nervous system disorders. The company has a collaboration agreement with twoXAR, Inc. to develop prodrug-based therapies for multiple therapeutic areas and indications. The company was founded in 2006 and is headquartered in Coralville, Iowa.
Stocks in other countries: United Kingdom India Canada Australia
Market Cap
Volume (24h)